KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Payables (2016 - 2025)

Historic Payables for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $108.6 million.

  • Supernus Pharmaceuticals' Payables rose 4328.32% to $108.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.6 million, marking a year-over-year increase of 4328.32%. This contributed to the annual value of $76.4 million for FY2024, which is 404.3% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Payables stood at $108.6 million for Q3 2025, which was up 4328.32% from $77.7 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Payables high stood at $498.3 million for Q4 2022, and its period low was $70.1 million during Q1 2021.
  • Its 5-year average for Payables is $131.3 million, with a median of $82.6 million in 2024.
  • Examining YoY changes over the last 5 years, Supernus Pharmaceuticals' Payables showed a top increase of 45667.43% in 2023 and a maximum decrease of 8403.22% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Payables (Quarter) stood at $117.7 million in 2021, then skyrocketed by 323.43% to $498.3 million in 2022, then tumbled by 84.03% to $79.6 million in 2023, then decreased by 4.04% to $76.4 million in 2024, then soared by 42.25% to $108.6 million in 2025.
  • Its last three reported values are $108.6 million in Q3 2025, $77.7 million for Q2 2025, and $76.9 million during Q1 2025.